Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors

Lung cancer has a high prevalence, with a growing number of new cases and mortality every year. Furthermore, the survival rate of patients with non-small-cell lung carcinoma (NSCLC) is still quite low in the majority of cases. Despite the use of conventional therapy such as tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Amelia, Tasia, Kartasasmita, Rahmana Emran, Ohwada, Tomohiko, Tjahjono, Daryono Hadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838133/
https://www.ncbi.nlm.nih.gov/pubmed/35164092
http://dx.doi.org/10.3390/molecules27030819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838133/
https://www.ncbi.nlm.nih.gov/pubmed/35164092
http://dx.doi.org/10.3390/molecules27030819

Ejemplares similares